查看購物車
  • Simplified Chinese
  • Japanese
  • Korean
細胞治療與基因治療市場：交易分析（2021-2024）
市場調查報告書
商品編碼
1483204

細胞治療與基因治療市場：交易分析（2021-2024）

Cell and Gene Therapy Deals Analysis, 2021-2024
出版日期: | 出版商: Kalorama Information | 英文 345 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告考察了細胞治療和基因治療市場，並全面介紹了動態且快速發展的細胞和基因治療市場。它重點關注 2021 年第一季至 2024 年第一季的關鍵交易，為希望瞭解和利用塑造這一快速成長產業的趨勢的公司和利害關係人提供了寶貴的見解。

目錄

第 1 章執行摘要

第二章創投與民間融資

  • 流動的創投/私募資金

第三章策略投資

  • 細胞和基因療法的策略性投資

第 4 章 IPO、FPO、SPAC

  • 在北美，IPO、FPO 和 SPAC 收入佔大部分收入

第五章併購（M&A）

  • 儘管平均價值下降，但併購數量仍在增加

第 6 章技術/研究/策略合作

  • CGT 市場呈現多元化合作

第 7 章許可

  • 細胞和基因治療市場的許可水準穩定

第 8 章製造與供應鏈

  • CGT 的製造和供應鏈管理活動顯著成長

第 9 章分銷與協作行銷

  • CGT 銷售與聯合行銷協議摘要

第10章其他-合資、重組、解散、分立

  • 關於影響細胞和基因治療的其他類型的交易
簡介目錄
Product Code: 24-022

"Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024" is published in two installments, the first in Q2 2024 and the second in Q4 2024. Customers who purchase the report will receive both installments.

Kalorama Information's "Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024" offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and stakeholders looking to understand and leverage the trends shaping this burgeoning field.

No report published by a major market research publisher has tackled the cell and gene therapy dealmaking space more comprehensively. With cell and gene therapy is becoming a highly competitive marketplace, over a thousand companies are specifically referenced in this report.

Why This Report?

With over 1,500 companies actively involved in the cell and gene therapy space, understanding the trends and competitive landscape is crucial for strategic planning. "Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024" provides the essential market analysis needed to navigate and capitalize on the opportunities within this fast-growing industry.

Report Highlights:

  • Quarterly Funding Trends (Q1 2021-Q1 2024): Graphical representation of funding amounts, showcasing investment influx in cell and gene therapy.
  • Deal Types: Comprehensive categorization of 2000+ deals, including venture capital, private investments, mergers, acquisitions, strategic collaborations, licensing, manufacturing/ supply, and distribution/ co-marketing.
  • Top Deal-Makers: Identification of the most active companies by deal type and overall deal activity.
  • Regional Deal Breakdown: Percentage analysis of deal-making activities across different regions.

Who Should Buy This Report

Understanding the volumes of deals that have been made, who is making which type and how many, and the deals' details, is critical to finding how to take advantage of the opportunities in one of the fastest-growing markets.

Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 is designed to provide companies entering or already in this market with knowledge of the trends in deals that will shape future growth and competition.

The following is just some of the information in this report:

  • Quarterly Funding Amounts Q1 2021- Q1 2024 by Type and Region
  • Specific details of 2000+ CGT Deals
  • Venture Capital/Private Funding Round Amounts, By Quarter
  • Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)
  • Deals by Type - Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
  • Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)
  • Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)

Methodology

The report's insights are derived from a blend of primary and secondary research, including interviews with industry professionals, comprehensive literature reviews, and analysis of company and government reports.

Table of Contents

Chapter 1: Executive Summary

  • Introduction
  • $35 Billion in Investment in 2023
    • Figure 1-1: Total Deals per Month, April 2021-April 2024 (count)
    • Figure 1-2: Total Deals per Month, by Type [VC/ Private, IPO/FPO/SPAC; and All Other Deals], April 2021-April 2024 (count)
  • Quarterly Funding Amounts
    • Table 1-1: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], Q1 2024 (in millions $)
    • Table 1-2: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2023 (in millions $)
    • Table 1-3: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2022 (in millions $)
    • Table 1-4: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021 (in millions $)
    • Table 1-5: Total Quarterly Funding, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021-Q1 2024 (in millions $)
    • Figure 1-3: Total Quarterly Funding, Q1 2021- Q1 2024 (in millions $)
    • Figure 1-4: Total Quarterly Funding, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], Q1 2021-Q1 2024 (in millions $)
  • Quarterly Funding Category Shares, Q1 2021 Through Q1 2024
    • Table 1-6: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2023 (%)
    • Table 1-7: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2022
    • Table 1-8: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021 (%)
    • Table 1-9: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], 2021-Q1 2024 (%)
    • Figure 1-5: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv], Q1 2021-Q1 2024 (%)
    • Figure 1-6: January-April 2024 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-7: 2023 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-8: 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-9: 2021 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Quarterly Deal Counts by Category, Q1 2021 - Q1 2024
    • Table 1-10: Quarterly Count of Deals, Q1 2024, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal] (total number) (%)
    • Table 1-11: Quarterly Count of Deals, By 2023 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal] (total number) (%)
    • Table 1-12: Quarterly Count of Deals, by 2022 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture] (total number) (%)
    • Table 1-13: Quarterly Count of Deals, by 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture] (total number) (%)
    • Table 1-14: Yearly Shares of Number of Deals, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], 2021-2024 partial (%)
  • Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy
    • Figure 1-10a: Yearly Shares of Number of Deals, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain], 2021-2024 partial (%)
    • Figure 1-10b: Yearly Shares of Number of Deals, By Category [Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], 2021-2024 partial (%)
    • Figure 1-11: Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain], Q1 2021-Q1 2024 (Total number)
  • A Look at Less Frequent CGT Deal Types
    • Figure 1-12: Lower Frequency Deal Types, by Quarter, by Category [Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], Q1 2021-Q1 2024 (total number)
    • Figure 1-13: Merger/Acquisition Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Figure 1-14: Venture Capital/Private Funding Round Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Figure 1-15: IPO/FPO Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Figure 1-16: SPAC Portion Amount, by Year, 2021-2023 (in millions $)
  • Most Active Companies
    • Table 1-15: Most Active Companies in CGT Deals, Collaborations, Overall 2021-April 2024
    • Figure 1-17: Most Active Companies in CGT Deals, Collaborations, Overall 2021-April 2024

Chapter 2: Venture Capital & Private Funding

  • VC/Private Funding in Flux
    • Figure 2-1: Total Number of Private Funding/VC Rounds, by Month, Jan 2021-April 2024 (count)
    • Figure 2-2: Average Private Funding/VC Round Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 2-1: Regional Venture Capital/Private Funding, by Region [North America, Europe, APAC, Rest of World], by Quarter Q1 2021-Q1 2024 (in millions $) (%)
    • Figure 2-3: Quarterly Venture Capital/Private Total Funding, by Region [North America, Europe, APAC, Rest of World], Q1 2021-Q1 2024 (in millions $)
    • Table 2-2: Regional Venture Capital/Private Funding Shares, by Region [North America, Europe, APAC, Rest of World], by Quarter Q1 2021-Q1 2024 (%)
    • Figure 2-4: Regional Venture Capital/Private Funding Shares, by Region [North America, Europe, APAC, Rest of World], by Quarter, Q1 2021-Q1 2024, (%)
    • Figure 2-5: Venture Capital/Private Funding Round Amounts, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Figure 2-6: Scaled Venture Capital/Private Funding Round Amounts, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 2-3: Venture Capital/Private Fundraising Deals, Q1 2024
    • Table 2-4: Venture Capital/Private Fundraising Deals, Q4 2023
    • Table 2-5: Venture Capital/Private Fundraising Deals, Q3 2023
    • Table 2-6: Venture Capital/Private Fundraising Deals, Q2 2023
    • Table 2-7: Venture Capital/Private, Q1 2023
    • Table 2-8: Venture Capital/Private Fundraising Deals, Q4 2022
    • Table 2-9: Venture Capital/Private Fundraising Deals, Q3 2022
    • Table 2-10: Venture Capital/Private, Q2 2022
    • Table 2-11: Venture Capital/Private, Q1 2022

Chapter 3: Strategic Investments

  • Strategic Investments in Cell and Gene Therapy
    • Figure 3-1: Total Number of Strategic Investments, By Quarter, Q1 2021-Q1 2024 (count)
    • Figure 3-2: Average Strategic Investment Amount, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Figure 3-3: Total Strategic Investment Amount, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 3-1: Strategic Investment Total Amounts, Counts, and Averages, by Quarter, Q1 2021-Q1 2024, (in millions $)
    • Table 3-2: Strategic Investments, January 2021-April 2024
    • Table 3-3: Most Active in Acquisition/Merger/Strategic Investment, 2021-April 2024
    • Figure 3-4: Most Active in Acquisition/Merger/Strategic Investment, 2021-April 2024

Chapter 4: IPOs, FPOs, & SPACs

  • North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs
    • Figure 4-1: Total Number of IPOs/ FPOs, By Month, January 2021-April 2024 (count)
    • Figure 4-2: Average IPO/ FPO Proceeds, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 4-1: Quarterly IPO/ FPO Total Funding, by Region [North America, Europe, APAC], Q1 2021-Q1 2024 (in millions $)
    • Figure 4-3: Total IPO/FPO Funding, by Quarter, by Region [North America, Europe, APAC], Q1 2021-Q1 2024 (in millions $)
    • Table 4-2: Regional IPO/FPO Funding Shares, by Quarter [North America, Europe, APAC], Q1 2021-Q1 2024 (%)
    • Figure 4-4: Regional IPO/FPO Funding Shares, By Quarter, Q1 2021-Q1 2024 [North America, APAC, and Europe) (%)
    • Figure 4-5: IPO/FPO Amounts, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 4-3: Quarterly SPAC Funding Portion, Q1 2021-Q1 2024 (in millions $)
    • Figure 4-6: Quarterly SPAC Funding Portion Total and Average, Q1 2021-Q1 2024 (in millions $)
    • Table 4-4: IPO/FPO Deals, January -May 2024 (in millions $)
    • Table 4-5: IPO/FPO Deals, Q4 2023 (in millions $)
    • Table 4-6: IPO/FPO Deals, Q3 2023 (in millions $)
    • Table 4-7: IPO/FPO Deals, Q2 2023 (in millions $)
    • Table 4-8: IPO/FPO Deals, Q1 2023 (in millions $)
    • Table 4-9: IPO/FPO Deals, Q4 2022 (in millions $)
    • Table 4-10: IPO/FPO Deals, Q3 2022 (in millions $)
    • Table 4-11: IPO/FPO Deals, Q2 2022 (in millions $)
    • Table 4-12: IPO/FPO Deals, Q1 2022 (in millions $)
    • Table 4-13: SPAC Portion, Q1 2021-Q1 2024 (in millions $)
    • Figure 4-7: SPAC Portion Amount, by Year, 2021-2023 (in millions $)

Chapter 5: Mergers & Acquisitions (M&A)

  • Growing Numbers of M&A, Despite Lower Average Value
    • Figure 5-1: Total Number of Mergers and Acquisitions, by Month, January 2021-April 2024 (count)
    • Figure 5-2: Average Merger/Acquisition Amount, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 5-1: Quarterly Merger and Acquisition Values, Counts, and Averages, Q1 2021-Q1 2024 (in millions $) (Total count)
    • Figure 5-3: Merger/ Acquisition Transactions Global Total, By Quarter [Q1 2022- Q1 2024] (in millions $)
    • Figure 5-4: Merger/Acquisition Amounts, by Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 5-2: Mergers and Acquisitions Announcements, January-May 2024 (in millions $)
    • Table 5-3: Mergers and Acquisitions Announcements, Q4 2023 (in millions $)
    • Table 5-4: Mergers and Acquisitions Announcements, Q3 2023 (in millions $)
    • Table 5-5: Mergers and Acquisitions Announcements, Q2 2023 (in millions $)
    • Table 5-6: Mergers and Acquisitions Announcements, Q1 2023 (in millions $)
    • Table 5-7: Mergers and Acquisitions, Q4 2022 (in millions $)
    • Table 5-8: Mergers and Acquisitions, Q3 2022 (in millions $)
    • Table 5-9: Mergers and Acquisitions, Q2 2022 (in millions $)
    • Table 5-10: Mergers and Acquisitions, Q1 2022 (in millions $)
    • Table 5-11: Most Active in Acquisition/Merger/ Strategic Investment, 2021-April 2024 (count)
    • Figure 5-5: Most Active in Acquisition/Merger/Strategic Investment, 2021-April 2024

Chapter 6: Technology/Research/Strategic Collaborations

  • CGT Market Sees a Broad Variety of Collaborations
    • Figure 6-1: Total Number of Tech/Research/Strategic Collaborations, By Month, January 2021-April 2024 (count)
    • Figure 6-2: Total Number of Collaborations with Upfront and/or Milestone Payments, By Quarter, Q1 2021-Q1 2024 (in millions $)
    • Table 6-1: Collaboration Upfront and Future/Milestone Payments, Counts, Averages, Q1 2021-Q1 2024 (in millions $) (count)
    • Figure 6-3: Average Collaboration Upfront Payment, By Quarter, Q2 2021-Q1 2024 (in millions $)
    • Figure 6-4: Research Collaboration Upfront Payments Total, By Quarter, Q2 2021-Q1 2024 (in millions $)
    • Figure 6-5: Average Collaboration Future/Milestone Payments, By Quarter, Q2 2021-Q1 2024 (in millions $)
    • Figure 6-6: Total Collaboration Future/ Milestone Payments, By Quarter, Q2 2021-Q1 2024 (in millions $)
    • Table 6-2: Technology/Research/Strategic Collaboration Deals, January-May 2024
    • Table 6-3: Technology/Research/Strategic Collaboration Deals, Q4 2023
    • Table 6-4: Technology/Research/Strategic Collaboration Deals, Q3 2023
    • Table 6-5: Technology/Research/Strategic Collaboration Deals, Q2 2023
    • Table 6-6: Technology/Research/Strategic Collaboration Deals, Q1 2022-Q1 2023
    • Table 6-7: Most Active in Research/Strategic Collaborations, 2021-April 2024 (count)
    • Figure 6-7: Most Active in Research/ Strategic Collaborations, 2021-April 2024 (count)

Chapter 7: Licensing

  • Stable Levels of Licensing in the Cell and Gene Therapy Market
    • Figure 7-1: Total Number of Licensing Deals, By Month, January 2021-April 2024 (count)
    • Table 7-1: Licensing Deals, January-April 2024
    • Table 7-2: Licensing Deals, Q4 2023
    • Table 7-3: Licensing Deals, Q3 2023
    • Table 7-4: Licensing Deals, Q2 2023
    • Table 7-5: Licensing Deals, Q1 2022-Q1 2023
    • Table 7-6: Most Active Companies in Licensing Deals, 2021-April 2024 (count)
    • Figure 7-2: Most Active Companies in Licensing Deals, 2021-April 2024 (count)

Chapter 8: Manufacturing and Supply Chain

  • Major Growth in Manufacturing and Supply Chain Management Activity in CGT
    • Figure 8-1: Total Number of Supply/Manufacturing Deals, By Month, January 2021-April 2024 (count)
    • Table 8-1: Manufacturing and Supply Chain Deals, January-May 2024
    • Table 8-2: Manufacturing and Supply Chain Deals, Q4 2023
    • Table 8-3: Manufacturing and Supply Chain Deals, Q3 2023
    • Table 8-4: Manufacturing and Supply Chain Deals, Q2 2023
    • Table 8-5: Manufacturing and Supply Chain Deals, Q1 2022-Q1 2023
    • Table 8-6: Most Active Companies in Manufacturing/Supply Deals, 2021-April 2024 (count)
    • Figure 8-2: Most Active Companies in Manufacturing/Supply Deals, 2021-April 2024 (count)

Chapter 9: Distribution & Co-Marketing

  • A Look at CGT Distribution and Co-Marketing Deals
    • Figure 9-1: Total Number of Distribution/ Co-Marketing Deals, by Month, January 2021-April 2024 (count)
    • Table 9-1: Distribution & Co-Marketing Deals, January-May 2024
    • Table 9-2: Distribution & Co-Marketing Deals, Q4 2023
    • Table 9-3: Distribution & Co-Marketing Deals, Q3 2023
    • Table 9-4: Distribution & Co-Marketing Deals, Q2 2023
    • Table 9-5: Distribution & Co-Marketing Deals, Q1 2022-Q1 2024
    • Table 9-6: Most Active Companies in Manufacturing/ Supply Deals, 2021-April 2024 (count)
    • Figure 9-2: Most Active Companies in Manufacturing/ Supply Deals, 2021-April 2024 (count)

Chapter 10: Other - JV, Restructuring, Termination, Spinoffs

  • A Look at Other Types of Deals Impacting Cell and Gene Therapy
    • Figure 10-1: Total Number of JV, Restructuring, Termination, By Month [January 2021-April 2024 ] (Total count)
    • Table 10-1: Restructuring, JV, Termination, Spinoffs, January 2022-April 2024